Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review

Clinical Rheumatology

Volumn 36, Issue 6, 2017, Pages 1437-1444

  Jafri, Kashif ^a   Zahed, Hengameh ^a   Wysham, Katherine D ^a   Patterson, Sarah ^a   Nolan, Amber L ^a   Bucknor, Matthew D ^a   Chaganti, R Krishna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse medication effect; Myopathy; Seizures; Systemic lupus erythematosus

Indexed keywords

ACICLOVIR; C REACTIVE PROTEIN; CEFAZOLIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATINE KINASE; DAPSONE; ESCITALOPRAM; FAMOTIDINE; GLUCOSE; HEMOGLOBIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LA ANTIBODY; LEVETIRACETAM; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RIBONUCLEOPROTEIN; RO ANTIBODY; SM ANTIBODY; ANTIMALARIAL AGENT;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ADD ON THERAPY; ADULT; ALOPECIA; ANISOCORIA; ANTIBIOTIC THERAPY; ANTIBODY TITER; ANTIPROTOZOAL THERAPY; ARM WEAKNESS; ARTIFICIAL VENTILATION; ASIAN AMERICAN; BLOOD PRESSURE MEASUREMENT; BRAIN BIOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR ACCIDENT; COMPLEMENT BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; CYTOPENIA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; DYSPNEA; ELECTROENCEPHALOGRAM; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX ENCEPHALITIS; HOSPITAL DISCHARGE; HUMAN; HYPERTRANSAMINASEMIA; HYPOXIA; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUMBAR PUNCTURE; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MUSCLE STRENGTH; MYALGIA; MYOPATHY; MYOSITIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT DEPARTMENT; PANCYTOPENIA; PATIENT TRANSPORT; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUADRIPLEGIA; RASH; REVIEW; SEIZURE; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOCYTE COUNT; TONIC CLONIC SEIZURE; TRANSTHORACIC ECHOCARDIOGRAPHY; X-RAY COMPUTED TOMOGRAPHY; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; MUSCLE DISEASE; PATHOLOGY; QUADRICEPS FEMORIS MUSCLE; ULTRASTRUCTURE;

ADULT; ANTIMALARIALS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUSCULAR DISEASES; QUADRICEPS MUSCLE; QUADRIPLEGIA; SEIZURES;

EID: 85013773569     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-017-3579-8     Document Type: Review

References (29)

1. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28. doi:10.1136/ard.2008.101766
2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26. doi:10.1002/art.39480
3. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of O (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123(6):1386–1394. doi:10.1016/j.ophtha.2016.01.058
4. Casado E, Gratacos J, Tolosa C, Martinez JM, Ojanguren I, Ariza A, Real J, Sanjuan A, Larrosa M (2006) Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 65(3):385–390. doi:10.1136/ard.2004.023200
5. Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS (1995) Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 34(2):166–170
6. Delanty N, Vaughan CJ, French JA (1998) Medical causes of seizures. Lancet 352(9125):383–390. doi:10.1016/S0140-6736(98)02158-8
7. Filipovich A, McClain K, Grom A (2010) Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant 16(1 Suppl):S82–S89. doi:10.1016/j.bbmt.2009.11.014
8. Schulert GS, Grom AA (2014) Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol 28(2):277–292. doi:10.1016/j.berh.2014.03.002
9. Li J, Wang Q, Zheng W, Ma J, Zhang W, Wang W, Tian X (2014) Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore) 93(2):100–105. doi:10.1097/MD.0000000000000022
10. Popescu A, Kao AH (2011) Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol 9(3):449–457. doi:10.2174/157015911796557984
11. Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F, Ceruti S, Trotta F (2016) The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. doi:10.1016/j.jaut.2016.06.013
12. Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y (2015) Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 13:43. doi:10.1186/s12916-015-0269-8
13. Hanly JG (2004) ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 13(11):861–864
14. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69(12):2074–2082. doi:10.1136/ard.2010.130476
15. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM (2016) Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs 76(4):459–483. doi:10.1007/s40265-015-0534-3
16. Dhand UK (2006) Clinical approach to the weak patient in the intensive care unit. Respir Care 51(9):1024–1040 discussion 1040-1021
17. Saguil A (2005) Evaluation of the patient with muscle weakness. Am Fam Physician 71(7):1327–1336
18. Zoma A (2004) Musculoskeletal involvement in systemic lupus erythematosus. Lupus 13(11):851–853
19. Pasnoor M, Barohn RJ, Dimachkie MM (2014) Toxic myopathies. Neurol Clin 32(3):647–670. doi:10.1016/j.ncl.2014.04.009viii
20. Valiyil R, Christopher-Stine L (2010) Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep 12(3):213–220. doi:10.1007/s11926-010-0104-3
21. Gupta A, Gupta Y (2013) Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 17(5):913–916. doi:10.4103/2230-8210.117215
22. Stauber WT, Hedge AM, Trout JJ, Schottelius BA (1981) Inhibition of lysosomal function in red and white skeletal muscles by chloroquine. Exp Neurol 71(2):295–306
23. Siddiqui AK, Huberfeld SI, Weidenheim KM, Einberg KR, Efferen LS (2007) Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 131(2):588–590. doi:10.1378/chest.06-1146
24. Nord JE, Shah PK, Rinaldi RZ, Weisman MH (2004) Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33(5):336–351
25. Posada C, Garcia-Cruz A, Garcia-Doval I, Millan BS, Teijeira S (2011) Chloroquine-induced myopathy. Lupus 20(7):773–774. doi:10.1177/0961203310385553
26. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, Ratliff NB (1987) Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 82(3):447–455
27. Lonesky TA, Kreuter JD, Wortmann RL, Rhodes CH (2009) Hydroxychloroquine and colchicine induced myopathy. J Rheumatol 36(11):2617–2618. doi:10.3899/jrheum.081315
28. Tselios K, Gladman DD, Su J, Urowitz MB (2016) Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus. Lupus 25(5):532–535. doi:10.1177/0961203315617845
29. Abdel-Hamid H, Oddis CV, Lacomis D (2008) Severe hydroxychloroquine myopathy. Muscle Nerve 38(3):1206–1210. doi:10.1002/mus.21091